Subscribe
Share
Share
Embed
Lower blood pressure target after stroke cuts cardiovascular events; FDA grants priority review to Huntington gene therapy; sevasemten fails in Becker
Targeting systolic blood pressure under 120 mm Hg after ischemic stroke or transient ischemic attack reduced major cardiovascular events in the 4,368-patient OPTIMAL-STROKE trial, published Nov. 7 in the New England Journal of Medicine.
The Food and Drug Administration accepted uniQure's gene therapy application for Huntington disease for priority review, and Servier said sevasemten failed in a pivotal Becker muscular dystrophy trial.
Read this week's roundup and its sources: https://physicianintheloop.org/specialties/neurology/2026-11-01/
Get this roundup by email, free
The voices on this episode are generated by AI, and so is the script, from the week's specialty roundup at Physician in the Loop. Every fact in the roundup links to its source.
The week's innovation news in neurology for neurologists, every Sunday in a few minutes: new technology, AI tools, devices, FDA decisions and new ways of delivering care. From the Specialties pages of Physician in the Loop, where every story links to its sources: physicianintheloop.org/specialties/neurology/. Read by AI voices.
Voice 1: This is Physician in the Loop, the weekly neurology briefing, for November 1st to November 7th, 2026.
Voice 1: A trial found that pushing systolic blood pressure under 120 after a stroke or a transient ischemic attack cut cardiovascular events compared with a target under 140.
Voice 2: How many patients, and how much of a difference did it make?
Voice 1: The open-label OPTIMAL-STROKE trial enrolled nearly 4,400 patients with high blood pressure and a prior ischemic stroke or transient ischemic attack across 30 sites in Brazil. Over nearly four years of follow-up, the composite of cardiovascular death, nonfatal heart attack, nonfatal stroke or hospitalization for unstable angina or heart failure occurred in about 11% of the under-120 group versus roughly 14% of the under-140 group, a hazard ratio of 0.79 that the trial called statistically significant. The results were published in the New England Journal of Medicine and presented at the American Heart Association Scientific Sessions.
Voice 2: Was there any downside to the lower target?
Voice 1: Yes. Renal outcomes were more common with the intensive, under-120 treatment than with the under-140 target, about 4% versus about 2%.
Voice 2: The FDA has accepted uniQure's application for its Huntington disease gene therapy, with priority review.
Voice 1: What's the timeline, and what data is it based on?
Voice 2: uniQure said the FDA set a target action date of May 1, 2027, for the therapy, called ifezuntirgene inilparvovec, filed under the accelerated approval pathway. The application compares phase 1/2 data from 51 dosed patients with a propensity score-matched external control drawn from the Enroll-HD natural history database. The company said the FDA is tentatively planning an advisory committee meeting, and that the therapy could become the first disease-modifying treatment for Huntington disease.
Voice 1: A follow-up on a drug readout this week: Servier said sevasemten failed in a pivotal Becker muscular dystrophy trial.
Voice 2: What did the trial measure, and did it miss everything?
Voice 1: The 18-month, placebo-controlled GRAND CANYON trial tested sevasemten against the North Star Ambulatory Assessment as its primary end point, and Servier said there was no statistically significant benefit. The company said secondary end points also were not met.
Voice 2: Servier said the drug showed a continued favorable safety and tolerability profile, and that it is still analyzing the full dataset, with results to be presented later. The company described the findings as topline and not yet peer reviewed.
Voice 1: Sources and corrections are at physicianintheloop.org, where you can sign up for the free email briefing. This briefing was read by AI voices.